To ask the Secretary of State for Health, what steps he plans to take against Concordia as a result of the Competition and Markets Authority findings announced on 21 November 2017 that Concordia had overcharged the NHS for the provision of Liothyronine tablets.
12 December 2017
The Competition and Markets Authority has provisionally found that Concordia abused its dominant position to overcharge the National Health Service by millions for liothyronine tablets. A provisional decision does not necessarily lead to an infringement decision. Where companies have breached competition law, the Department will seek damages and invest that money back into the NHS.